Conference Reports for NATAP

The Liver Meeting Washington DC October 2017 Back

Can HCV be eliminated among HIV---infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates       [from Jules: a key remaining barrier to eliminating HCV]   AASLD: INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015 - (11/10/17)   EACS: High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)   CROI: A Systematic HCV-RNA Screening in HIV+ MSM Reveals a High Number of Potential Transmitters: 5% HCV Prevalence, 17% acute HCV incidence, higher rates of condomless sex, IDU, syphillis - (03/07/17)   CROI: High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17)   AASLD: HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B - (10/26/17)   AASLD: Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study - (11/16/17)   EACS: The Burden of HCV-Related Cirrhosis Among HIV/HCV Coinfected Individuals in Spain in the DAA Era: What will the battlefield look like once the battle is over? - (11/02/17)   Reported by Jules Levin American Association for the Study of Liver Diseases (AASLD 2017), Washington, DC, October 20-24, 2017